NAVIGATING FACILITATED REGULATORY PATHWAYS DURING A DISEASE X PANDEMIC

Murray M. Lumpkin, M.D., M.Sc.
Bill and Melinda Gates Foundation
Lead for Global Regulatory Strengthening Initiatives

WHO Health Emergencies Programme
Meeting on Pathogen X
Virtual Presentation
30 August 2022
LIFE CYCLE OF MEDICAL PRODUCTS TARGETED TO LMICs

Regulatory authorisation is a necessary step, but not sufficient alone to enable access & impact. Obtaining a WHO policy recommendation and meeting procurers’ requirements are integral components of country uptake of new interventions.
FACILITATED REGULATORY AND ETHICS COMMITTEE AUTHORISATION OF CLINICAL TRIALS

- WHO AFRO/EMRO and HQ – AVAREF Programme
  - Multi-national clinical trials application joint assessment (regulatory and ethics committees)
  - From all African nations where trial to be conducted
  - Pivoted to virtual platform – actually expedited procedures and made more inclusive and robust
  - Pan-African webinars to keep regulators and ethics committees informed and get on-going input
  - Able to bring trial sponsors, outside experts, regulators, ethics committees
  - 14 countries, 5 languages → 90% of participating countries authorised protocol within 31 days of joint assessment and positive opinion

- Ethics Committees remain a challenge as much less history of harmonisation or joint assessment
- WHO could help further remedy this before next pandemic or develop was for ethics committees to rely on the joint assessments more than was the experience this time
- Overall model other WHO regions might wish to initiate
90% of authorities who participated in the DNDi joint-review were able to deliver decisions within 31 days or less

| Participation | Countries       | Working days to decision |
|---------------|-----------------|--------------------------|
| Full participation by both NRA and NEC | Burkina Faso | 24 days |
|               | Guinea Conakry  | 16 days                  |
|               | Ivory Coast     | 23 days                  |
|               | Kenya           | 27 days                  |
|               | Niger           | 16 days                  |
|               | Uganda          | tbc                      |
| Partial Participation from country, either NRA or NEC | Cameroon       | 12 days                  |
|               | DRC             | 13 days                  |
|               | Ghana           | 31 days                  |
|               | Mozambique      | 33 days                  |
| Did not participate in the entire joint review process | Mali           | 29 days                  |
|               | Ethiopia        | tbc                      |
|               | Sudan           | tbc                      |
|               | Equatorial Guinea | tbc         |

- 4 Countries able to deliver decisions in 16 days or fewer
- 5 Countries able to deliver decisions in between 17-31 days
- 1 Country was able to deliver a decision between 32-62 days
WHO Coordinated Scientific Advice (CSA) Procedure

- Advice process whereby product developers may approach WHO and obtain joint advice from WHO Prequalification and the WHO Technical Department(s) in areas of unmet public health needs
- Improve understanding of WHO requirements / data needs for both PQ and Policy Guidelines
- Pilot phase during pandemic
- Can cover non-clinical, clinical, and manufacturing quality issues
- Standardized process with single entry point / timelines for responses (both WHO and developer)
- Increase predictability and minimise misunderstanding and delays

- Initial reports have been favourable
- Would like to see it become “business as usual” for products for unmet needs (pandemic and non-pandemic)
FACILITATED PATHWAYS TO MARKETING AUTHORISATION (INITIAL AND SUBSEQUENT VARIATIONS)

• EUL, EUA, and Conditional Authorisation
  • Vaccine EULs subsequent to joint assessments with EMA and also full for products not going through EMA
  • Prequalification teams not staffed for the numbers of products coming to them during pandemic
  • Did extraordinary job, given their resources – worked with and relied on EMA and other reference agencies when they could; did full assessments when they could not
  • Impact in not only the work of the PQ Teams, but also the Regulatory Teams in RPQ and the WHO regional and country offices who developed procedures for facilitating national authorisations through regulatory reliance-based pathways
    • In 2020 and 2021, PQT shared 470 EUL dossiers and reports with around 100 national regulatory authorities and the RPQ teams (both PQ and REG) worked with 150 LMIC NRAs to support ~3,300 regulatory authorisations (both initial and subsequent variations) of the 10 EULed COVID vaccines at that time
    • Through these facilitated pathways and reliance-based regulatory pathways, product authorisation at the national levels as not a rate-limiting step to product access
FACILITATED PATHWAYS TO MARKETING AUTHORIZATION
(INITIAL AND SUBSEQUENT VARIATIONS)

• Challenges
  • Not able to surge assessment and inspection teams quickly to meet demand
    • Historically depended on member state national agencies to help supply needed consultants to add to capacity when needed
    • National agencies also with very stretched bandwidth – so not able to provide assessment resources as in the past
    • Need to consider ways to surge capacity quickly in a pandemic situation, especially when national agencies will also be stretched
      - Ready cadre of consultants not in national agencies
      - On going training / preparation / usage of consultants

• Timing of generic versions of innovative products (when innovator not marketing to LICs and/or not pursuing prequalification)
  • Access to final product for bioequivalence trials
  • Interaction with program divisions on policy guidances – especially data availability
CONCLUSION

• Facilitated regulatory pathways and those colleagues implementing them played a pivotal role in expediting the development, assessment, and authorisation of quality products to address the COVID pandemic
• Many good learnings from the COVID experience which we would want to maintain and further enhance
• Some challenges that also need to be examined and mitigation strategies implemented so that these are not challenges for the next pandemic
Thank you